10
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Patient Preference and Adherence (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the growing importance of patient preference and adherence throughout the therapeutic process. Sign up for email alerts here.

      34,896 Monthly downloads/views I 2.314 Impact Factor I 3.8 CiteScore I 1.14 Source Normalized Impact per Paper (SNIP) I 0.629 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the patient perspective, and capture the “patient voice” describing how CIM impacts their daily lives.

          Participants and Methods

          Online survey of participants with breast, lung, or colorectal cancer who had received chemotherapy within the past 12 months and experienced ≥1 episode of CIM in the past year. Participants were asked to answer close-ended questions and provide qualitative responses to: “In your own words, please describe how side effects from myelosuppression have impacted your life.”

          Results

          Among 301 survey participants, fatigue was the most frequently reported side effect of chemotherapy; 55% of participants rated fatigue as highly bothersome (9 or 10 on a 1–10 scale of “bothersomeness”). Participants rated symptoms associated with CIM, including fatigue, weakened immune system (infections), bleeding and/or bruising, and shortness of breath, as being as bothersome as other side effects of chemotherapy, including alopecia, neuropathy, and nausea/vomiting. Overall, 24–43% of participants thought that CIM and its symptoms had a negative impact on their daily lives, including their ability to complete tasks at home and work, and to socialize. Qualitative responses supported these findings; participants highlighted that CIM-related symptoms, particularly fatigue and fear of infections, affected their ability to be physically active, complete work, or continue meaningful relationships with friends and family.

          Conclusion

          Participants described a real-world impact of CIM that often isolates them from family and friends, and means that they are unable to work or perform tasks of daily living. Using measures that help patients to recognize and communicate the signs and symptoms of CIM might increase the likelihood of maintaining daily lives as close to normal as possible, during and after chemotherapy treatment.

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          NCCN Guidelines Insights: Colon Cancer, Version 2.2018

          The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

            The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

              Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
                Bookmark

                Author and article information

                Journal
                Patient Prefer Adherence
                Patient Prefer Adherence
                ppa
                ppa
                Patient preference and adherence
                Dove
                1177-889X
                25 February 2021
                2021
                : 15
                : 453-465
                Affiliations
                [1 ]Epstein Health, LLC. , Woodcliff Lake, NJ, USA
                [2 ]LUNGevity Foundation , Bethesda, MD, USA
                [3 ]Clinique De Genolier , Genolier, Switzerland
                [4 ]G1 Therapeutics Ltd ., Research Triangle Park, NC, USA
                [5 ]HealthiVibe, a Division of Corrona, LLC ., Arlington, VA, USA
                [6 ]Chapel Hill Consulting, LLC., Chapel Hill, NC, USA
                [7 ]UNC Gillings School of Global Public Health , Chapel Hill, NC, USA
                [8 ]Duke University Medical Center , Durham, NC, USA
                Author notes
                Correspondence: Robert S Epstein Epstein Health, LLC. , Woodcliff Lake, NJ, 07677, USATel +1 201-285-5800 Email repstein@epsteinhealth.com
                Author information
                http://orcid.org/0000-0001-5031-302X
                http://orcid.org/0000-0002-9627-6727
                Article
                292462
                10.2147/PPA.S292462
                7920579
                33658769
                90bf2b9d-ef0d-423a-895d-2faa2ba2a25e
                © 2021 Epstein et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 17 November 2020
                : 19 January 2021
                Page count
                Figures: 2, Tables: 11, References: 43, Pages: 13
                Funding
                Funded by: G1 Therapeutics, Inc. (Research Triangle Park, NC, USA);
                This study was funded by G1 Therapeutics, Inc. (Research Triangle Park, NC, USA). The study sponsor was involved in study design; collection, analysis and interpretation of data; writing the report, and in the decision to submit the article for publication.
                Categories
                Original Research

                Medicine
                cancer,chemotherapy,myelosuppression,real world,quality of life,patient burden
                Medicine
                cancer, chemotherapy, myelosuppression, real world, quality of life, patient burden

                Comments

                Comment on this article